

GLAND PHARMA LIMITED

February 27, 2024

BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers 25th floor, Dalal Street Mumbai - 400 001 Scrip Code: 543245 National Stock Exchange of India Limited Listing Department Exchange Plaza, 5th floor Plot no. C-1, Block G, Bandra Kurla Complex Bandra (East), Mumbai - 400 051 Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Appointment of *President* for Phixen S.A.S. (Cenexi); the wholly-owned step-down subsidiary of Gland Pharma Limited

We would like to inform you that Phixen S.A.S (which carries on the business under the name 'Cenexi'), a wholly owned step-down subsidiary of Gland Pharma Limited, has appointed Mr. Alain Kirchmeyer as its *President* replacing Jim McPherson (Coaching and Consulting) Limited ("JMCL"); effective 27th February, 2024.

Please note that Phixen S.A.S is not a material subsidiary of the Company as on 31st March 2023; but may be qualified as a Material Subsidiary as on 31st March 2024, and this disclosure is made voluntarily, as a practice of better corporate governance.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are given in **Annexure-A** enclosed herewith.

This is for your information and records.

Yours truly, For Gland Pharma Limited

Sampath Kumar Pallerlamudi Company Secretary and Compliance Officer

Encl: Annexure A



Annexure A

Details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Details of Mr. Alain Kirchmeyer

SI. No	Particulars	Remarks
1	Reason for change & Date of Change	Mr. Alain Kirchmeyer, has been appointed as the <i>President</i> for Phixen S.A.S, replacing Jim McPherson (Coaching and Consulting) Limited (JMCCL), effective 27 th February, 2024.
2	Brief profile	Mr. Alain Kirchmeyer holds a master's degree in Engineering from Mines ParisTech, France and has over 30 years of experience in various B2B industries (materials, electrical equipment and pharmaceuticals).
		He has a vast experience performing all kinds of roles ranging from a project manager to President in various companies viz., Engie, Saint-Gobain, Schneider Electric, Hager, etc.
		Mr. Alain in his previous leadership roles, was the Managing Director for Civil Networks Europe, President (for Europe) of Morgan Advanced Materials, President of Carbon and Technical Ceramics.
		In 2019, Mr. Alain transitioned into the pharmaceutical sector: he joined Unither Pharmaceuticals, a leading CDMO specialising in sterile fill & finish activities and world leader in Blow Fill Seal technology, as their COO, before being promoted to the Managing Director position in 2020. In 2022, he joined Delpharm, a leading European generalist CDMO, and became its CEO.
		As the group makes strategic progress in achieving the goals at Cenexi, Alain's leadership will help in building customer relationship, expansion of the capacities, and a solid client-centric mindset to the role.
3	Disclosure of relationships between director	NA